false
0001098009
0001098009
2026-08-18
2026-08-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 18, 2026
America Great Health
(Exact
name of registrant as specified in charter)
wyoming
(State
or other jurisdiction of incorporation)
| 0-27873 |
|
98-0178621 |
| (Commission
File Number) |
|
(IRS Employer
Identification No.) |
1609 W Valley Blvd., #338,
Alhambra, CA 91803 |
|
28277 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (626) 576-1299
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| |
|
|
|
|
Item
8.01. Other Events.
Clinical
Observation Study of Ion-Modified Peptide Products
America
Great Health (the “Company”) is providing an update regarding a clinical observation study involving ion-modified peptide
products identified in the study as AX-3 (“Ion Peptide No. 1”) and PPY-3 (“Ion Peptide No. 4”).
The
clinical observation study was conducted at Zhejiang Kangjing Hospital in China during the period from December 2024 through May 2026.
According to the study report provided to the Company, the study evaluated the use of the ion-modified peptide products as adjunctive
treatment in a total of ten subjects, consisting of eight subjects with solid tumors, one subject with malignant lymphoma, and one subject
with bronchiectasis accompanied by hemoptysis.
The
eight subjects with solid tumors included five subjects with lung cancer or lung cancer with metastatic disease, two subjects with colorectal
cancer, and one subject with liver cancer. Certain subjects had significant underlying medical conditions or advanced disease.
The
study was observational in nature and the ion-modified peptide products were administered as adjunctive treatment rather than as stand-alone
cancer therapy. The solid-tumor subjects had received or were receiving other forms of treatment, including chemotherapy, radiation therapy,
surgery and/or targeted therapy. Accordingly, the observed outcomes cannot be attributed solely to the ion-modified peptide products.
The
hospital’s report describes observations at baseline and, where available, approximately one month, three months and six months
after initiation of adjunctive treatment. The observations included clinical symptoms, vital signs, peripheral blood measurements, lipid-related
measurements and certain immune-cell measurements.
According
to the report, certain subjects experienced improvements in reported clinical symptoms during the observation period. The underlying
patient data also reflect changes over time in certain measured parameters. The results, however, varied among subjects and across measured
parameters.
Two
subjects with advanced malignancies and significant underlying disease died approximately 25 days and 22 days, respectively, after beginning
the observation period and were withdrawn from the study. The hospital report states that both subjects had advanced disease complicated
by multiple-organ failure.
The
hospital report further states that, based on the observations reported, no significant treatment-related toxicity or adverse effects
were identified among the study subjects, other than a reported issue regarding discomfort associated with swallowing the relatively
large capsules.
Limitations
of the Observations
The
Company cautions investors that the study was a small, preliminary clinical observation involving only ten subjects and was not a randomized,
blinded or placebo-controlled clinical trial.
In
addition, the subjects had heterogeneous diseases, stages of disease, underlying conditions and treatment histories. The subjects with
solid tumors also received other therapeutic interventions, including chemotherapy, radiation therapy, surgery and/or targeted therapies.
These factors substantially limit the ability to determine whether any observed clinical changes were caused by the ion-modified peptide
products.
The
hospital report itself acknowledges that the use of concurrent or prior cancer therapies limits the ability to independently evaluate
the effect of the ion-modified peptide products based on changes in tumor morphology observed through imaging.
Accordingly,
the observations described in the report should not be interpreted as establishing the safety or efficacy of AX-3, PPY-3 or any other
Company product for the diagnosis, treatment, mitigation, cure or prevention of cancer or any other disease. Additional research, including
appropriately designed controlled clinical studies, would be required to evaluate safety and efficacy.
The
Company views the hospital report as preliminary observational information that may assist the Company in evaluating potential future
research and development activities relating to its ion-modified peptide technology.
Copies
of the hospital’s clinical observation report and the accompanying patient observation tables are furnished as Exhibits 99.1 and
99.2 to this Current Report on Form 8-K.
The
Company will continue to evaluate the results of the observation study and potential next steps. There can be no assurance that these
observations will be replicated in additional studies, that future studies will produce favorable results, or that any product based
on the Company’s ion-modified peptide technology will receive regulatory approval or be successfully commercialized.
Forward-Looking
Statements
This
Current Report on Form 8-K contains forward-looking statements, including statements concerning the Company’s evaluation of the
clinical observation results, potential future research and development activities, additional studies, regulatory activities and the
potential development or commercialization of products utilizing ion-modified peptide technology. Forward-looking statements are subject
to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by such
statements.
Such
risks and uncertainties include, among others, the preliminary and observational nature of the reported results; the small number and
heterogeneous characteristics of the subjects; the absence of a randomized control group; the use of concurrent or prior therapies; the
Company’s ability to reproduce or validate the reported observations in larger and appropriately controlled studies; the risks
and uncertainties inherent in product development and clinical research; regulatory requirements applicable to the Company’s products
and activities; and the other risks described in the Company’s filings with the Securities and Exchange Commission.
Readers
are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes
no obligation to update any forward-looking statement to reflect events or circumstances after the date of this report.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 99.1 |
|
Zhejiang Kangjing Hospital Clinical Observation Study Report Regarding Ion-Modified Peptide Adjunctive Treatment |
| 99.2 |
|
Patient Observation Data Tables Relating to Ion-Modified Peptide Adjunctive Treatment |
| 104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned
hereunto duly authorized.
Date:
August 24, 2026
| |
AMERICA GREAT HEALTH |
| |
|
| |
By: |
/s/ Mike Wang |
| |
Name: |
Mike Wang |
| |
Title: |
President |
Exhibit 99.1
Zhejiang
Kangjing Hospital
Clinical
Trial Report
Evaluation
of a Clinical Observational Study of Ion-Modified Peptides
as Adjunctive Therapy for Solid Tumors
| Study
period |
Document
status |
| December 2024–May 2026 |
Interim Summary |
I.
Investigational Products, Methods, and Dosages
A.
Investigational products
AX-3
(Ion Peptide No. 1) and PPY-3 (Ion Peptide No. 4).
B.
Methods and dosages
Patients
with tumors: Four PPY-3 capsules (Ion Peptide No. 4) after breakfast and four AX-3 capsules (Ion Peptide No. 1) after dinner.
Patients
with inflammatory disease (bronchiectasis with inflammation): Three AX-3 capsules (Ion Peptide No. 1) after breakfast and after dinner.
II.
Description of the 10 Selected Participants
Ten
participants were selected for the clinical observational study of ion-modified peptides as adjunctive therapy, as shown in Table 1.
A.
General information
| 1. | Age
and sex: Eight participants had solid tumors and ranged from 23 to 81 years of age (six men and two women). One 34-year-old woman had
a hematologic malignancy—malignant lymphoma. One 39-year-old woman had an inflammatory condition—bronchiectasis with hemoptysis. |
| 2. | Tumor
types: The eight solid-tumor cases comprised five cases of lung cancer, including lung cancer with mediastinal, brain, or intrapulmonary
metastases; two cases of rectal cancer; and one case of liver cancer. |
| 3. | Comorbidities:
Among the eight participants with solid tumors, three had chronic obstructive pulmonary disease (COPD) with respiratory failure, one
had obstructive pneumonia, and one had diabetes. The remaining three had no complications other than the diagnosed tumor. |
| 4. | Deaths
among participants with tumors: A 65-year-old man with advanced liver cancer and respiratory failure died after 25 days of treatment.
An 81-year-old man with rectal cancer with lung metastasis, diabetes, and COPD died after 22 days of treatment. Both participants withdrew
from the clinical observational study of ion-modified peptide adjunctive therapy. |
B.
Two participants with other diseases
| 5. | Malignant
lymphoma: A 34-year-old woman diagnosed with malignant lymphoma participated in and completed the clinical observational study of ion-modified
peptide adjunctive therapy. |
| 6. | Bronchiectasis:
A 39-year-old woman diagnosed with bronchiectasis with hemoptysis participated in and completed the clinical observational study of ion-modified
peptide adjunctive therapy. |
C.
Summary Evaluation of the Clinical Observational Study
1.
Role of ion-modified peptides added to standard antitumor therapy
All
eight selected participants with solid tumors received combination treatment. Each had undergone radiotherapy, chemotherapy, or surgery.
Outcomes following the addition of ion-modified peptide adjunctive therapy were considered acceptable.
Representative
Case 1: Mr. Wu Junbo, a 23-year-old man, was diagnosed with lung cancer with a solitary brain metastasis. He received a single session
of CyberKnife radiosurgery to the brain metastatic lesion (24 Gy per session). He did not receive chemotherapy, interventional treatment,
or other surgery; however, he had received osimertinib targeted therapy for more than three years. Ion-modified peptide adjunctive therapy
was added to this treatment, with a reported marked therapeutic response.
Representative
Case 2: Mr. Chen Jianzhong, a 71-year-old man, was diagnosed with rectal cancer. After surgery and two cycles of moderate-dose chemotherapy,
he received ion-modified peptide adjunctive therapy, with a reported marked therapeutic response.
2.
Analysis of the two deaths and withdrawals
Both
participants with tumors died from advanced disease complicated by multiple-organ failure. This suggests that future eligibility criteria
should exclude patients with malignant tumors accompanied by multiple-organ failure. Otherwise, assessment of the effects or efficacy
of ion-modified peptide adjunctive therapy in a clinical observational study may be confounded.
3.
Clinical observations in malignant lymphoma
The
study included one 34-year-old woman diagnosed with malignant lymphoma. During three cycles of chemotherapy for malignant lymphoma, she
also received ion-modified peptide adjunctive therapy. Her condition was considered acceptable. Detailed observational data are provided
in Tables 1–5.
4.
Clinical observations in bronchiectasis
The
study included one 39-year-old woman diagnosed with bronchiectasis with hemoptysis. Ion-modified peptide adjunctive therapy was administered
together with anti-infective treatment and symptomatic treatment for cough and sputum. The condition was controlled, hemoptysis resolved,
and cough and sputum production improved markedly. Overall recovery was considered acceptable. Detailed observational data are provided
in Tables 1–5.
5.
Limitations of the clinical observational study
The
eight participants with solid tumors had received baseline chemotherapy, radiotherapy, surgery, or targeted therapy. Consequently, changes
in tumor size assessed by CT or B-mode ultrasonography could not be attributed independently to ion-modified peptide adjunctive therapy
with sufficient confidence. No evaluation of this endpoint is therefore provided at this stage; this constitutes a limitation of the
clinical observational study. In contrast, observations and assessments of blood biochemistry (including blood lipids), peripheral complete
blood counts, immune-cell function, and clinical vital signs may have greater clinical relevance and value.
6.
Summary of the safety evaluation
The
selected participants received the investigational products (ion-modified peptides) in accordance with the specified doses and methods.
As shown in Tables 1–5, no significant changes were observed in peripheral complete blood counts, blood biochemistry and lipid
profiles, oxygen saturation, immune-cell measurements, or vital signs, indicating no statistically significant differences. The report
therefore concludes that ion-modified peptide adjunctive therapy demonstrated a favorable safety profile and that no toxic or adverse
effects were observed among the participants. A small number of patients reported mild discomfort when swallowing because the oral ion-modified
peptide capsules were relatively large; consideration should be given to producing smaller capsules in the future.
Project
Lead: Hospital Director Hao Jian
Exhibit 99.2
1. Clinical Efficacy of Ion-Peptide Adjunctive Therapy in Patients
with Solid Tumors
| No. |
Name |
Sex |
Age
(years) |
Diagnosis |
Before
Treatment |
|
1
Month After Treatment |
|
3
Months After Treatment |
|
6
Months After Treatment |
| Respiratory |
Gastrointestinal |
|
Respiratory |
Gastrointestinal |
|
Respiratory |
Gastrointestinal |
|
Respiratory |
Gastrointestinal |
| 1 |
Wu
Junbo |
Male |
23 |
Lung
cancer with brain metastasis |
Irritative
choking cough, dyspnea, and chest tightness |
None |
|
Irritative
choking cough, dyspnea, and chest tightness resolved |
None |
|
No
chest tightness or dyspnea; no cough or sputum production. |
None |
|
No
chest tightness or dyspnea; no cough or sputum production. |
None |
| 2 |
Jin
Deshui |
Male |
72 |
Lung
cancer with mediastinal metastasis |
Mild
cough and sputum production, accompanied by chest tightness and discomfort. |
None |
|
Cough
resolved; slight sputum production remained; chest tightness and discomfort resolved. |
None |
|
No
cough, sputum production, or chest tightness. |
None |
|
No
cough, sputum production, or chest tightness. |
None |
| 3 |
Chen
Jianzhong |
Male |
71 |
Rectal
cancer |
None |
Mild
abdominal pain and distension, with alternating constipation and diarrhea. |
|
None |
Mild
abdominal pain and distension improved; no alternating constipation and diarrhea. |
|
None |
No
abdominal pain or distension; no constipation or diarrhea. |
|
None |
No
abdominal pain or distension; no constipation or diarrhea. |
| 4 |
Liu
Quandang |
Male |
78 |
Advanced
lung cancer and advanced COPD |
Marked
cough and sputum production, with pronounced dyspnea, chest tightness, and palpitations. |
None |
|
Mild
cough and moderate sputum production; dyspnea and chest tightness improved; palpitations resolved. |
None |
|
Mild
cough and sputum production; dyspnea and chest tightness improved; no palpitations. |
None |
|
Mild
cough and sputum production; dyspnea and chest tightness improved. |
None |
| 5 |
Chen
Jiangna |
Female |
34 |
Malignant
lymphoma |
No
cough or sputum production; chest tightness and palpitations, accompanied by low- to moderate-grade fever. |
Mild
abdominal distension, no diarrhea, and poor appetite. |
|
No
obvious respiratory symptoms, but chest tightness and palpitations were present, with irregular low- to moderate-grade fever. |
Mild
abdominal distension, no diarrhea, and poor appetite. |
|
Chest
tightness and palpitations persisted, as did irregular low- to moderate-grade fever. |
Abdominal
distension decreased; no diarrhea; poor appetite. |
|
Chest
tightness and palpitations persisted, with irregular low-grade fever. |
Mild
abdominal distension, no diarrhea, and poor appetite. |
| 6 |
Zhang
Haixiang |
Female |
58 |
Left
upper-lobe lung cancer with obstructive pneumonia |
Moderate-grade
fever and marked cough with sputum production, accompanied by dyspnea and chest tightness; no palpitations. |
None |
|
Occasional
low-grade fever; cough and sputum production decreased, with dyspnea and chest tightness. |
None |
|
No
fever; mild cough without sputum production; dyspnea and chest tightness persisted. |
None |
|
No
fever, cough, or sputum production; dyspnea and chest tightness improved. |
None |
| 7 |
Zhao
Pingni |
Female |
64 |
Diffuse
lung cancer |
Marked
cough and sputum production, with dyspnea and palpitations. |
None |
|
Predominantly
cough and dyspnea, accompanied by palpitations, chest tightness, and fatigue. |
None |
|
Cough
and dyspnea remained predominant; accompanying palpitations, chest tightness, and fatigue improved. |
None |
|
Cough
and dyspnea decreased; palpitations and chest tightness persisted; no fatigue. |
None |
| 8 |
Zhang
Chun |
Male |
65 |
Advanced
liver cancer with respiratory failure |
Advanced
liver cancer with extensive lung metastases, causing extreme dyspnea and respiratory failure. |
Massive
ascites with abdominal distension and pain; cachectic state. |
|
Extreme
dyspnea further worsened; respiratory failure accompanied by heart failure. |
Massive
ascites progressively worsened, with persistent abdominal distension and pain; cachexia worsened. |
|
Deceased |
|
|
|
|
| 9 |
Zhao
Pingxiao |
Male |
81 |
Rectal
cancer with lung metastasis, diabetes, and COPD |
Marked
cough and sputum production with severe shortness of breath and dyspnea, cyanotic lips, and respiratory failure. |
Persistent
marked abdominal distension and pain, pronounced poor appetite, and constipation. |
|
Shortness
of breath and dyspnea with extreme breathing difficulty and respiratory failure. |
Persistent
marked abdominal distension and pain with massive ascites; extremely poor appetite and almost no food intake. |
|
Deceased |
|
|
|
|
| 10 |
Gao
Jun |
Female |
39 |
Bronchiectasis |
Marked
cough and sputum production; expectoration of bright-red blood, approximately 50 mL/day, with chest tightness, fatigue, and shortness
of breath. |
None |
|
Cough
and sputum production markedly decreased; no hemoptysis; chest tightness, shortness of breath, and fatigue remained. |
None |
|
Cough
persisted; no sputum production or hemoptysis; chest tightness and fatigue, but no shortness of breath. |
None |
|
Occasional
cough; no sputum production, hemoptysis, shortness of breath, chest tightness, or fatigue. |
None |
2. Changes in Vital Signs
During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors
| No. |
Name |
Sex |
Age
(years) |
Diagnosis |
Before
Treatment |
|
|
1
Month After Treatment |
|
|
3
Months After Treatment |
|
|
6
Months After Treatment |
|
| Respiratory
Rate (breaths/min) |
Pulse
(beats/min) |
Heart
Rate (beats/min) |
Oxygen
Saturation (SO2%) |
Blood
Pressure (mmHg) |
|
Respiratory
Rate (breaths/min) |
Pulse
(beats/min) |
Heart
Rate (beats/min) |
SO2
(%) |
Blood
Pressure (mmHg) |
|
Respiratory
Rate (breaths/min) |
Pulse
(beats/min) |
Heart
Rate (beats/min) |
SO2
(%) |
Blood
Pressure (mmHg) |
|
Respiratory
Rate (breaths/min) |
Pulse
(beats/min) |
Heart
Rate (beats/min) |
SO2
(%) |
Blood
Pressure (mmHg) |
| 1 |
Wu
Junbo |
Male |
23 |
Lung
cancer with brain metastasis |
22 |
72 |
72 |
98 |
126/78 |
|
21 |
68 |
81 |
99 |
120/72 |
|
24 |
68 |
70 |
99 |
122/72 |
|
20 |
66 |
66 |
100 |
118/70 |
| 2 |
Jin
Deshui |
Male |
72 |
Lung
cancer with mediastinal metastasis |
21 |
84 |
84 |
95 |
138/88 |
|
24 |
90 |
81 |
94 |
140/78 |
|
26 |
80 |
80 |
95 |
129/78 |
|
22 |
78 |
77 |
94 |
139/85 |
| 3 |
Chen
Jianzhong |
Male |
71 |
Rectal
cancer |
24 |
82 |
82 |
98 |
140/86 |
|
19 |
77 |
78 |
98 |
138/76 |
|
22 |
76 |
77 |
97 |
134/84 |
|
24 |
74 |
74 |
98 |
140/88 |
| 4 |
Liu
Quandang |
Male |
78 |
Advanced
lung cancer and advanced COPD |
28 |
90 |
90 |
91 |
145/92 |
|
29 |
94 |
94 |
93 |
150/90 |
|
30 |
85 |
84 |
92 |
138/88 |
|
26 |
82 |
81 |
93 |
140/78 |
| 5 |
Chen
Jiangna |
Female |
34 |
Malignant
lymphoma |
26 |
86 |
86 |
96 |
138/87 |
|
30 |
91 |
91 |
96 |
138/82 |
|
24 |
80 |
78 |
97 |
127/77 |
|
20 |
82 |
84 |
96 |
136/82 |
| 6 |
Zhang
Haixiang |
Female |
58 |
Left
upper-lobe lung cancer with obstructive pneumonia |
28 |
90 |
90 |
96 |
150/90 |
|
27 |
94 |
94 |
92 |
146/94 |
|
24 |
88 |
86 |
92 |
142/84 |
|
22 |
84 |
83 |
93 |
138/82 |
| 7 |
Zhao
Pingni |
Female |
64 |
Diffuse
lung cancer |
27 |
78 |
78 |
92 |
146/87 |
|
30 |
84 |
84 |
94 |
142/90 |
|
22 |
72 |
72 |
95 |
136/82 |
|
23 |
70 |
69 |
94 |
142/87 |
| 8 |
Zhang
Chun |
Male |
65 |
Advanced
liver cancer with respiratory failure |
32 |
102 |
114 |
89 |
152/100 |
|
34 |
87 |
88 |
78 |
156/96 |
|
|
Deceased |
|
|
|
|
|
|
|
|
|
| 9 |
Zhao
Pingxiao |
Male |
81 |
Rectal
cancer with lung metastasis, diabetes, and COPD |
34 |
111 |
111 |
90 |
149/96 |
|
36 |
99 |
105 |
74 |
149/96 |
|
|
Deceased |
|
|
|
|
|
|
|
|
|
| 10 |
Gao
Jun |
Female |
39 |
Bronchiectasis |
26 |
80 |
80 |
|
128/78 |
|
26 |
80 |
80 |
99 |
128/78 |
|
22 |
78 |
78 |
98 |
136/82 |
|
20 |
72 |
70 |
100 |
130/74 |
3. Changes in Peripheral
Blood Counts During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors
| No. |
Name |
Sex |
Age
(years) |
Diagnosis |
Before
Treatment |
|
1
Month After Treatment |
|
3
Months After Treatment |
|
6
Months After Treatment |
| WBC
(×10⁹/L) |
Neutrophils
(%) |
Lymphocytes
(%) |
|
WBC
(×10⁹/L) |
Neutrophils
(%) |
Lymphocytes
(%) |
|
WBC
(×10⁹/L) |
Neutrophils
(%) |
Lymphocytes
(%) |
|
WBC
(×10⁹/L) |
Neutrophils
(%) |
Lymphocytes
(%) |
| 1 |
Wu
Junbo |
Male |
23 |
Lung
cancer with brain metastasis |
5.8 |
58.1 |
21.4 |
|
6.1 |
64.3 |
32.1 |
|
6.4 |
59.8 |
33.3 |
|
5.8 |
61.4 |
31.8 |
| 2 |
Jin
Deshui |
Male |
72 |
Lung
cancer with mediastinal metastasis |
6.1 |
68.3 |
24.3 |
|
7.5 |
62.8 |
32.1 |
|
7.2 |
58.2 |
27.4 |
|
6.8 |
69.7 |
21.1 |
| 3 |
Chen
Jianzhong |
Male |
71 |
Rectal
cancer |
7.4 |
70.8 |
24.1 |
|
6.7 |
64.2 |
31.2 |
|
5.8 |
66.3 |
27.6 |
|
5.3 |
56.8 |
33.2 |
| 4 |
Liu
Quandang |
Male |
78 |
Advanced
lung cancer and advanced COPD |
9.5 |
80.4 |
12.2 |
|
6.2 |
72.1 |
22.7 |
|
6.2 |
78.1 |
20.5 |
|
5.9 |
70.5 |
27.5 |
| 5 |
Chen
Jiangna |
Female |
34 |
Malignant
lymphoma |
8.9 |
28.3 |
62.6 |
|
9.6 |
25.9 |
65.9 |
|
8.3 |
24.7 |
66.3 |
|
8.1 |
23.4 |
65.2 |
| 6 |
Zhang
Haixiang |
Female |
58 |
Left
upper-lobe lung cancer with obstructive pneumonia |
10.2 |
85.8 |
10.5 |
|
8.5 |
73.2 |
20.7 |
|
7.5 |
68.7 |
28.5 |
|
6.4 |
65.1 |
30.3 |
| 7 |
Zhao
Pingni |
Female |
64 |
Diffuse
lung cancer |
12.3 |
82.3 |
11.2 |
|
8.2 |
70.5 |
23.7 |
|
6.5 |
67.4 |
31.4 |
|
7.6 |
70.2 |
29.5 |
| 8 |
Zhang
Chun |
Male |
65 |
Advanced
liver cancer with respiratory failure |
11.2 |
88.1 |
9.4 |
|
13.4 |
90.5 |
8.7 |
|
Deceased |
|
|
|
|
|
|
| 9 |
Zhao
Pingxiao |
Male |
81 |
Rectal
cancer with lung metastasis, diabetes, and COPD |
14.2 |
90.2 |
8.7 |
|
18.7 |
91.6 |
7.1 |
|
Deceased |
|
|
|
|
|
|
| 10 |
Gao
Jun |
Female |
39 |
Bronchiectasis |
8.1 |
56.5 |
23.7 |
|
6.9 |
59.8 |
29.1 |
|
5.7 |
56.2 |
30.2 |
|
6.1 |
57.2 |
27.9 |
4. Changes in Lipid Profile
During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors (Unit: mol/L)
| No. |
Name |
Sex |
Age
(years) |
Diagnosis |
Before
Treatment |
|
1
Month After Treatment |
|
3
Months After Treatment |
|
6
Months After Treatment |
| Total
Cholesterol (TC) |
Triglycerides
(TG) |
HDL
Cholesterol (HDL-C) |
LDL
Cholesterol (LDL-C) |
|
TC |
TG |
HDL-C |
LDL-C |
|
TC |
TG |
HDL-C |
LDL-C |
|
TC |
TG |
HDL-C |
LDL-C |
| 1 |
Wu
Junbo |
Male |
23 |
Lung
cancer with brain metastasis |
4.2 |
1.5 |
2.3 |
2.9 |
|
3.8 |
1.6 |
2.0 |
3.2 |
|
5.2 |
1.2 |
1.8 |
2.8 |
|
4.8 |
1.6 |
3.2 |
2.3 |
| 2 |
Jin
Deshui |
Male |
72 |
Lung
cancer with mediastinal metastasis |
3.8 |
2.3 |
1.1 |
3.1 |
|
4.1 |
2.8 |
1.4 |
2.9 |
|
4.9 |
1.8 |
2.0 |
3.2 |
|
5.1 |
2.1 |
3.6 |
2.7 |
| 3 |
Chen
Jianzhong |
Male |
71 |
Rectal
cancer |
4.4 |
2.6 |
1.4 |
2.9 |
|
3.8 |
2.2 |
1.6 |
3.3 |
|
4.6 |
1.7 |
1.7 |
3.5 |
|
4.9 |
2.3 |
2.5 |
3.1 |
| 4 |
Liu
Quandang |
Male |
78 |
Advanced
lung cancer and advanced COPD |
5.0 |
1.8 |
1.6 |
3.8 |
|
4.8 |
2.4 |
1.3 |
4.2 |
|
5.0 |
2.1 |
1.9 |
3.8 |
|
3.9 |
1.8 |
2.4 |
3.2 |
| 5 |
Chen
Jiangna |
Female |
34 |
Malignant
lymphoma |
3.4 |
2.1 |
1.4 |
2.7 |
|
3.5 |
3.1 |
1.7 |
3.1 |
|
5.3 |
2.3 |
2.1 |
3.4 |
|
5.2 |
1.9 |
2.6 |
2.9 |
| 6 |
Zhang
Haixiang |
Female |
58 |
Left
upper-lobe lung cancer with obstructive pneumonia |
5.6 |
1.7 |
1.7 |
2.5 |
|
4.9 |
1.6 |
1.5 |
3.3 |
|
4.8 |
1.8 |
1.7 |
4.0 |
|
5.0 |
1.6 |
2.9 |
3.7 |
| 7 |
Zhao
Pingni |
Female |
64 |
Diffuse
lung cancer |
3.4 |
2.2 |
1.2 |
2.7 |
|
3.1 |
1.8 |
1.7 |
2.9 |
|
5.3 |
2.2 |
2.0 |
3.5 |
|
5.5 |
2.4 |
2.2 |
4.1 |
| 8 |
Zhang
Chun |
Male |
65 |
Advanced
liver cancer with respiratory failure |
6.1 |
3.1 |
1.0 |
4.1 |
|
7.4 |
2.9 |
1.2 |
5.1 |
|
Deceased |
|
|
|
|
|
|
|
|
| 9 |
Zhao
Pingxiao |
Male |
81 |
Rectal
cancer with lung metastasis, diabetes, and COPD |
2.8 |
1.4 |
1.5 |
4.4 |
|
2.6 |
1.6 |
1.2 |
5.8 |
|
Deceased |
|
|
|
|
|
|
|
|
| 10 |
Gao
Jun |
Female |
39 |
Bronchiectasis |
4.5 |
1.6 |
1.6 |
3.1 |
|
3.9 |
1.7 |
2.1 |
2.9 |
|
4.5 |
1.7 |
2.1 |
2.9 |
|
3.9 |
1.4 |
1.6 |
3.0 |
5. Changes in Immune
Cells During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors
| No. |
Name |
Sex |
Age
(years) |
Diagnosis |
Before
Treatment (%) |
|
1
Month After Treatment (%) |
|
3
Months After Treatment (%) |
|
6
Months After Treatment (%) |
| CD3+CD8⁺ |
CD16+CD56⁺ |
|
CD3+CD8⁺ |
CD16+CD56⁺ |
|
CD3+CD8⁺ |
CD16+CD56⁺ |
|
CD3+CD8⁺ |
CD16+CD56⁺ |
| 1 |
Wu
Junbo |
Male |
23 |
Lung
cancer with brain metastasis |
79.83
|
16.94
|
|
32.33
|
48.30
|
|
26.32
|
88.58
|
|
83.44
|
79.98
|
| 2 |
Jin
Deshui |
Male |
72 |
Lung
cancer with mediastinal metastasis |
57.11
|
25.36
|
|
66.34
|
72.71
|
|
42.29 |
63.81
|
|
64.77
|
78.31
|
| 3 |
Chen
Jianzhong |
Male |
71 |
Rectal
cancer |
39.12
|
12.22
|
|
79.37
|
79.28
|
|
65.18
|
74.11 |
|
48.07 |
88.93
|
| 4 |
Liu
Quandang |
Male |
78 |
Advanced
lung cancer and advanced COPD |
44.23
|
65.27
|
|
62.79
|
24.45
|
|
77.25
|
74.36
|
|
20.07
|
33.41 |
| 5 |
Chen
Jiangna |
Female |
34 |
Malignant
lymphoma |
63.88
|
24.82
|
|
38.61
|
57.26
|
|
72.51 |
76.53
|
|
59.31
|
53.14
|
| 6 |
Zhang
Haixiang |
Female |
58 |
Left
upper-lobe lung cancer with obstructive pneumonia |
34.08
|
58.36
|
|
68.34
|
65.66
|
|
75.89 |
45.27
|
|
54.23
|
81.37
|
| 7 |
Zhao
Pingni |
Female |
64 |
Diffuse
lung cancer |
54.08
|
31.72
|
|
80.64
|
84.49
|
|
62.84
|
76.76
|
|
46.03
|
79.01
|
| 8 |
Zhang
Chun |
Male |
65 |
Advanced
liver cancer with respiratory failure |
16.49
|
18.58
|
|
17.99
|
5.39
|
|
Deceased |
|
|
|
|
| 9 |
Zhao
Pingxiao |
Male |
81 |
Rectal
cancer with lung metastasis, diabetes, and COPD |
14.33
|
12.97
|
|
13.48
|
9.61
|
|
Deceased |
|
|
|
|
| 10 |
Gao
Jun |
Female |
39 |
Bronchiectasis |
79.83
|
36.94
|
|
71.29
|
13.06
|
|
58.46 |
87.15
|
|
63.54 |
76.48 |
